Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis

LIANG Xiaoxiao; LYU Shuxian; CHEN Shixian; LI Xiao; LI Ling; HUANG Xin

doi:10.6039/j.issn.1001-0408.2023.08.17

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis

更新时间：2025-09-27

- Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis
- ZHONGGUO YAOFANG Vol. 34, Issue 8, Pages: 983-987(2023)
- 作者机构：
  
  1.山东中医药大学药学院，济南;250355
  2.山东第一医科大学第一附属医院（山东省千佛山医院）药学部，济南　250014
  3.山东第一医科大学药学院，济南　250000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.08.17
  CLC： R979.9
- Received：20 August 2022，
  
  Revised：2023-02-28，
  
  Published：30 April 2023
- 稿件说明：
移动端阅览
梁笑笑,吕淑贤,陈世贤,等.托伐普坦治疗低钠血症有效性与安全性的系统评价/Meta分析再评价[J].中国药房,2023,34(08):983-987.

LIANG Xiaoxiao,LYU Shuxian,CHEN Shixian,et al.Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis[J].ZHONGGUO YAOFANG,2023,34(08):983-987.
梁笑笑,吕淑贤,陈世贤,等.托伐普坦治疗低钠血症有效性与安全性的系统评价/Meta分析再评价[J].中国药房,2023,34(08):983-987. DOI： 10.6039/j.issn.1001-0408.2023.08.17.

LIANG Xiaoxiao,LYU Shuxian,CHEN Shixian,et al.Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis[J].ZHONGGUO YAOFANG,2023,34(08):983-987. DOI： 10.6039/j.issn.1001-0408.2023.08.17.

摘要

目的

对托伐普坦治疗低钠血症有效性和安全性的系统评价/Meta分析进行再评价。

方法

计算机检索中国知网、万方数据、维普网、中国生物医学文献服务系统、PubMed、Embase、the Cochrane Library，收集托伐普坦治疗低钠血症的系统评价/Meta分析，检索时限为建库起至2022年6月15日。筛选文献、提取资料后，采用PRISMA声明评价纳入文献的报告质量，采用AMSTAR2量表评价纳入文献的方法学质量，采用GRADE工具评价纳入文献结局指标的证据质量。

结果

共纳入6篇文献，其中1篇为系统评价，5篇为Meta分析，共56个结局指标。PRISMA评分为15.0～20.5分，报告质量均为中等。AMSTAR2量表评价结果显示，5篇文献的方法学质量等级为极低质量，1篇文献为低质量。GRADE证据质量评价结果显示，中级指标6个，低级指标13个，极低级指标35个，无法评价指标2个，造成降级的主要因素为局限性、不一致性、不精确性及发表偏倚。在有效性方面，托伐普坦可有效升高患者的血清钠浓度、增加尿量、降低体质量、缩小腹围、缓解水肿、降低丙氨酸转氨酶水平。在安全性方面，托伐普坦引起的总不良反应发生率存在争议，可能会增加患者口干、口渴、尿频、血清钠过度校正的发生风险。

结论

托伐普坦治疗低钠血症的有效性较好，安全性方面应避免血清钠过度校正的发生，但目前相关系统评价/Meta分析的报告质量、方法学质量和证据质量较低，可能会降低结果的可靠性，应谨慎解读。

Abstract

OBJECTIVE

To reevaluate systematic reviews/meta-analysis of efficacy and safety of tolvaptan for hyponatremia.

METHODS

Retrieved from CNKI， Wanfang Data， VIP， CBM， PubMed， Embase and the Cochrane Library database， systematic reviews/meta-analysis about tolvaptan for the treatment of hyponatremia were included from the inception to June 15， 2022. After screening literature and extracting data， the PRISMA statement， AMSTAR 2 scale and GRADE method were used to evaluate the reporting quality， methodological quality and evidence quality of the included literature， respectively.

RESULTS

A total of 6 articles were included， of which 1 was systematic review and 5 were meta-analysis， including 56 outcome indicators. All of the 6 studies had PRISMA scores ranging from 15.0 to 20.5， and the quality of them was moderate. Results of the AMSTAR 2 scale showed that the methodological quality of 5 literatures were very low， and the quality of 1 literature was low. The quality of GRADE evidence showed that there were 6 moderate-quality indicators， 13 low-quality indicators， 35 very low-quality indicators， and 2 indicators that could not be assessed due to missing data. The main factors causing degradation were limitations， inconsistency， imprecision and publication bias. In terms of efficacy， tolvaptan could effectively increase the level of serum sodium， increase urine volume， reduce body weight， reduce abdominal circumference， relieve edema， and reduce alanine transaminase level. In terms of safety， the incidence of total adverse drug reaction induced by tolvaptan was controversial； it may increase the risk of dry mouth， thirst， frequent urination or excessive correction of serum sodium.

CONCLUSIONS

Tolvaptan has great efficacy in the treatment of hyponatremia， but serum sodium overcorrection should be avoided in terms of safety. Relevant systematic reviews/meta-analysis have shortcomings of low reporting quality， methodological quality and evidence quality， which may reduce the reliability of the results， so the results should be treated with caution.

关键词

Keywords

references

PERI A . Management of hyponatremia：causes，clinical aspects，differential diagnosis and treatment [J ] . Expert Rev Endocrinol Metab ， 2019 ， 14 （ 1 ）： 13 - 21

RONDON-BERRIOS H ， AGABA E I ， TZAMALOUKAS A H . Hyponatremia：pathophysiology，classification，manifestations and management [J ] . Int Urol Nephrol ， 2014 ， 46 （ 11 ）： 2153 - 2165 .

HOORN E J ， ZIETSE R . Vasopressin-receptor antagonists [J ] . Future Cardiol ， 2010 ， 6 （ 4 ）： 523 - 534 .

US Food and Drug Administration . Samsca Drug Label [EB/OL ] .（ 2013-04-30 ）[ 2023-02-23 ] . https：//www.accessdata.fda.gov/drugsatfda_docs/label/2013/022275s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022275s009lbl.pdf .

FUKUI H ， SAITO H ， UENO Y ， et al . Evidence-based clinical practice guidelines for liver cirrhosis 2015 [J ] . J Gastroenterol ， 2016 ， 51 （ 7 ）： 629 - 650 .

徐小元，丁惠国，李文刚，等 . 肝硬化腹水及相关并发症的诊疗指南 [J ] . 实用肝脏病杂志， 2018 ， 21 （ 1 ）： 21 - 31 .

中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J ] . 中华心血管病杂志， 2018 ， 46 （ 10 ）： 760 - 789 .

郭皓，吴利娟，金哲，等 . 血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症和肝性水肿的系统评价 [J ] . 世界华人消化杂志， 2016 ， 24 （ 6 ）： 938 - 946 .

黄梦洁，闫静，叶玲，等 . 托伐普坦治疗心力衰竭合并低钠血症疗效的Meta分析 [J ] . 中国循证心血管医学杂志， 2021 ， 13 （ 12 ）： 1413 - 1417，1429 .

李春杏，刘桦 . 托伐普坦治疗肝硬化腹水伴低钠血症疗效与安全性的Meta分析 [J ] . 中国药房， 2018 ， 29 （ 6 ）： 833 - 838 .

张翔云，杜闪闪，祖冬妮，等 . 托伐普坦治疗低钠血症疗效及安全性的Meta分析 [J ] . 重庆医科大学学报， 2016 ， 41 （ 9 ）： 964 - 970 .

BHANDARI S ， PERI A ， CRANSTON I ， et al . A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans [J ] . Clin Endocrinol（Oxf）， 2017 ， 86 （ 6 ）： 761 - 771 .

LI B L ， FANG D ， QIAN C ， et al . Erratum to：the efficacy and safety of tolvaptan in patients with hyponatremia：a meta-analysis of randomized controlled trials [J ] . Clin Drug Investig ， 2017 ， 37 （ 4 ）： 411 - 413 .

HUNT H ， POLLOCK A ， CAMPBELL P ， et al . An introduction to overviews of reviews：planning a relevant research question and objective for an overview [J ] . Syst Rev ， 2018 ， 7 （ 1 ）： 39 .

PAGE M J ， MCKENZIE J E ， BOSSUYT P M ， et al . The PRISMA 2020 statement：an updated guideline for reporting systematic reviews [J ] . J Clin Epidemiol ， 2021 ， 134 ： 178 - 189 .

王靖，刘琴，翁淳光，等 . 国内公共卫生研究领域系统评价/Meta分析的质量评价 [J ] . 中国循证医学杂志， 2010 ， 10 （ 12 ）： 1367 - 1374 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

ATKINS D ， BEST D ， BRISS P A ， et al . Grading quality of evidence and strength of recommendations [J ] . BMJ ， 2004 ， 328 （ 7454 ）： 1490 .

STERNS R H . Adverse consequences of overly-rapid correction of hyponatremia [J ] . Front Horm Res ， 2019 ， 52 ： 130 - 142 .

TORRES V E ， CHAPMAN A B ， DEVUYST O ， et al . Tolvaptan in patients with autosomal dominant polycystic kidney disease [J ] . N Engl J Med ， 2012 ， 367 （ 25 ）： 2407 - 2418 .

US Food and Drug Administration . FDA drug safety communication：FDA limits duration and usage of samsca（tolvaptan）due to possible liver injury leading to organ transplant or death [EB/OL ] .（ 2013-04-30 ）[ 2022-07-18 ] . https：//www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-duration-and-usage-samsca-tolvaptan-due-possible-liver https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-duration-and-usage-samsca-tolvaptan-due-possible-liver .

Views

337

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Immune checkpoint inhibitors combined with neoadjuvant chemotherapy and adjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer： a meta-analysis

Network meta-analysis of first-line treatment of metastatic colorectal cancer with different chemotherapy combination regimens

Clinical evaluation of anlotinib in third-line treatment for advanced non-small cell lung cancer based on real-world data

Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer

Evaluation of the efficacy， safety and cost-effectiveness of different formulations of short-acting rhGH in the treatment of patients with short stature

Related Author

YANG Chunyan

ZHANG Shaohua

LI Rongkang

PENG Lei

ZHAO Li

BIE Jun

ZHANG Xiaoqing

LIU Shuai

Related Institution

Dept. of Oncology， Nanchong Hospital Affiliated to Beijing Anzhen Hospital， Capital Medical University （Nanchong Central Hospital）， Sichuan Nanchong

Dept. of Urology， South China Hospital Affiliated to Shenzhen University

Dept. of Urology， the Second Hospital of Lanzhou University

Inner Mongolia Clinical Medical College， Inner Mongolia Medical University

Day-care Unit， Inner Mongolia Armed Police Hospital

⁰